Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.tips.2017.06.006 http://scihub22266oqcxt.onion/10.1016/j.tips.2017.06.006 C5582618!5582618 !28734639     free     free     free Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\28734639 .jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Trends+Pharmacol+Sci 2017 ; 38 (9 ): 809-821 Nephropedia Template TP {{tp|p=28734639 |t=2017. FFA4/GPR120: Pharmacology and Therapeutic Opportunities |pdf=|usr=}}{{28734639 }} gab.com Text FFA4/GPR120: Pharmacology and Therapeutic Opportunities JO: Trends Pharmacol Sci http://www.kidney.de/pget.php?&tw=1&pmid=28734639 #FOAvip Free Fatty Acid receptor 4 (FFA4), also known as GPR120, is a G-protein-coupled receptor (GPCR) responsive to long-chain fatty acids that is attracting considerable attention as a potential novel therapeutic target for the treatment of type 2 diabetes mellitus (T2DM). Although no clinical studies have yet been initiated to assess efficacy in this indication, a significant number of primary publications and patents have highlighted the ability of agonists with potency at FFA4 to improve glucose disposition and enhance insulin sensitivity in animal models. However, the distribution pattern of the receptor suggests that targeting FFA4 may also be useful in other conditions, ranging from cancer to lung function. Here, we discuss and contextualise the basis for these ideas and the results to support these conclusions. Twit Text FOAVip FFA4/GPR120: Pharmacology and Therapeutic Opportunities ????Trends Pharmacol Sci http://www.kidney.de/pget.php?&tw=1&pmid=28734639 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=28734639 #FOAvip English Wikipedia <ref>{{Cite pmid|28734639 }}</ref> FFA4/GPR120: Pharmacology and Therapeutic Opportunities #MMPMID28734639 Milligan G ; Alvarez-Curto E ; Hudson BD ; Prihandoko R ; Tobin AB Trends Pharmacol Sci 2017[Sep]; 38 (9 ): 809-821 PMID28734639 show ga Free Fatty Acid receptor 4 (FFA4), also known as GPR120, is a G-protein-coupled receptor (GPCR) responsive to long-chain fatty acids that is attracting considerable attention as a potential novel therapeutic target for the treatment of type 2 diabetes mellitus (T2DM). Although no clinical studies have yet been initiated to assess efficacy in this indication, a significant number of primary publications and patents have highlighted the ability of agonists with potency at FFA4 to improve glucose disposition and enhance insulin sensitivity in animal models. However, the distribution pattern of the receptor suggests that targeting FFA4 may also be useful in other conditions, ranging from cancer to lung function. Here, we discuss and contextualise the basis for these ideas and the results to support these conclusions. |Animals [MESH] |Humans [MESH]FFA4/GPR120: Pharmacology and Therapeutic Opportunities (epmc).pdf DeepDyve Pubget Overpricing